

# INFECTION CONTROL<sup>AND</sup>

## HOSPITAL EPIDEMIOLOGY

Volume 11, Number 7 • July 1990

### EDITORIAL POLICY STATEMENT

- Duplicate Publication of a Manuscript** 341  
Richard P. Wenzel, MD, MSc;  
Dennis G. Maki, MD; Sue Crow, MSN, RN, CIC;  
William Schaffner, MD; John E. McGowan, Jr., MD

### ORIGINAL ARTICLES

- Control of Epidemic Methicillin-Resistant  
*Staphylococcus aureus*** 343  
Katherine A. Murray-Leisure, MD; Sandra Geib, RN;  
Diane Graceley; Arline B. Rubin-Slutsky, RN;  
Narendra Saxena, MD; H. Arnold Muller, MD;  
Bruce H. Hamory, MD
- Adverse Exposures and Universal Precautions  
Practices Among a Group of Highly Exposed  
Health Professionals** 351  
Mary E. Willy, MPH, BSN; Gita L. Dhillon, MS, CNM;  
Nancy L. Loewen, MS, CNM; Robert A. Wesley, PhD;  
David K. Henderson, MD

### SPECIAL COMMENTARIES

- The Influenza Vaccination Demonstration  
Project: An Expanded Policy Goal** 357  
David S. Fedson, MD
- Infection Control for Home Health  
Bryan Simmons, MD; Martha Trusler, RN;** 362  
Jane Roccaforte, MD; Philip Smith, MD;  
Rebecca Scott, RN

### AIDS

- Risky Business: Using Necessarily Imprecise  
Casualty Counts to Estimate Occupational  
Risks for HIV-I Infection** 371  
Susan E. Beekmann, BS; Barbara J. Fahey, BSN;  
Julie L. Gerberding, MD; David K. Henderson, MD

### EMPORIATRICS

- Emporiatrics: Protecting Travelers From Malaria** 380  
Mary D. Nettleman, MD

### STATISTICS FOR HOSPITAL EPIDEMIOLOGY

- Practical Considerations in Designing Data  
Collection Forms** 384  
Patricia A. Wasek, BA

### LETTERS TO THE EDITOR

- Pseudoepidemic of *Rhodotorula rubra* in  
Patients Undergoing Fiberoptic Bronchoscopy** 334  
Marian Kennedy, RN  
(Reply) William A. Rutala, PhD;  
Karen K. Hoffmann, RN, MS; David J. Weber, MD

- On Duplicate Publication of a Manuscript** 336  
W.H. Seto, MD; S.G. Ong, MD; T.Y. Ching, RN

- SHEA NEWSLETTER** 391

The Official Journal of The Society of Hospital Epidemiologists of America

From SmithKline Biologicals/  
Smith Kline & French Laboratories

# Engerix-B<sup>®</sup>

## Hepatitis B Vaccine (Recombinant)

### 0, 1, 2 Month Dosing Regimen for Certain Populations\*

**20 mcg recombinant  
dose helps to ensure  
immune response  
in adult patients of  
all ages**

**Choice of dosing  
regimens**

Adult dose (mcg)

Standard dosing regimen (0, 1 and 6  
months)

**New 0, 1, 2 month dosing regimen for  
certain populations\***

Published efficacy data: Neonates born  
of infected mothers<sup>†</sup>

VACTRAC<sup>™</sup>—computer software for  
vaccination tracking and compliance

Bar-coded, unit-dose vials

Lowest cost per dose<sup>‡</sup>

\*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

†Hepatitis B Vaccine (Recombinant), MSD.

‡Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

©SmithKline Beckman Corporation, 1990

# Lowest Cost Per Dose<sup>2</sup>

## Extensively Tested and Well Tolerated<sup>‡</sup>


State-of-the-art recombinant technology

14 million doses distributed in over 87 countries<sup>3</sup>

## Switch to 'Engerix-B'

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine<sup>3,4</sup>

Engerix-B®	Recombivax HB®†
20	10
Yes	Yes
Yes	No
Yes	Yes
Yes	No
Yes	No
Yes	No



Manufactured by  
**SmithKline Biologicals**  
Rixensart, Belgium

Distributed by  
**Smith Kline French Laboratories**  
Philadelphia, PA 19101

# Engerix-B®

## Hepatitis B Vaccine (Recombinant)

See complete prescribing information in SK&F literature or PDR. The following is a brief summary.

**INDICATIONS AND USAGE:** Engerix-B® is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. Immunization is recommended in persons of all ages, especially those who are or will be, at increased risk of exposure to hepatitis B virus.

**CONTRAINDICATIONS:** Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine.

**WARNINGS:** Do not give additional injections to patients experiencing hypersensitivity after an Engerix-B® injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had a unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

**PRECAUTIONS: General:** As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccine, delay administration, if possible, in persons with any febrile illness or active infection.

**Pregnancy:** Pregnancy Category C. Animal reproduction studies have not been conducted with Engerix-B®. It is also not known whether Engerix-B® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give Engerix-B® to a pregnant woman only if clearly needed.

**Nursing Mothers:** It is not known whether Engerix-B® is excreted in human milk. Because many drugs are excreted in human milk, use caution when giving Engerix-B® to a nursing woman.

**Pediatric Use:** Engerix-B® has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well. Maternally transferred antibodies do not interfere with the active immune response to the vaccine.

**ADVERSE REACTIONS:** Engerix-B® is generally well tolerated. During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between Engerix-B® and plasma-derived vaccines. In 36 clinical studies a total of 13,495 doses of Engerix-B® were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of Engerix-B®. Using a symptom checklist,\* the most frequently reported adverse reactions were injection site soreness (22%), and fatigue\* (14%). Other reactions are listed below.

**Incidence 1% to 10% of Injections:** Induration, erythema; swelling, fever (> 37.5%); headache\*, dizziness\*.

\*Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue or dizziness.

**Incidence < 1% of Injections:** Pain; pruritus; ecchymosis; sweating; malaise; chills; weakness; flushing; tingling; hypotension; influenza-like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain; cramps; vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain; rash; urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Additional adverse experiences have been reported with the commercial use of Engerix-B® outside the United States. Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests; migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guillain-Barré syndrome and Bell's palsy; transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances.

**Potential Adverse Experiences:** In addition, certain other adverse experiences not observed with Engerix-B® have been reported with Heptavax-B®† and/or Recombivax HB®‡. Those listed below are to serve as alerting information to physicians: Optic neuritis.

**HOW SUPPLIED:** 20 mcg/mL in Single-Dose Vials in packages of 1, 10 and 25 vials.

NDC 0007-3860-01 (package of 1)  
NDC 0007-3860-11 (package of 10)  
NDC 0007-3860-16 (package of 25)

10 mcg/0.5 mL in Single-Dose Vials in packages of 1 vial  
NDC 0007-3859-01 (package of 1)

† plasma-derived, Hepatitis B Vaccine, MSD  
‡ yeast-derived, Hepatitis B Vaccine, MSD

Manufactured by **SmithKline Biologicals**, Rixensart, Belgium  
Distributed by **SmithKline French Laboratories**  
Division of SmithKline Beckman Corp., Philadelphia, PA 19101

Date of issuance: Aug 1939

BAS-EB L6

© SmithKline Beckman Corporation, 1989

Engerix-B is a registered trademark of SmithKline Beckman Corporation

References:


1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278-3281.
2. Based on Medi-Span® Hospital Formulary Pricing Guide, December 1989.
3. Data on file, SK&F.
4. Bush L, Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989; 10:689.


# HATS OFF TO FIRST CLASS SERVICE


At SLACK Incorporated we believe our subscribers are first class people. That's why we do everything possible to publish first class journals. And, that's why we maintain a TOLL-FREE CUSTOMER SERVICE HOTLINE. For the first class customer service you deserve, call:


**1-800-257-8290**


Talk to a SLACK Customer Service Representative about:

 Subscriptions. Subscribing by phone is quick and easy; it only takes a minute and Visa and Mastercard are accepted.

 Renewals. Early subscription renewal helps avoid possible interruptions in service.

 Change of Address. Please notify us four weeks in advance to assure prompt delivery to your new address.

 Questions or Problems. Delivery problems or questions about your subscriptions can be handled instantly.



# SLACK

6900 Grove Road,  
Thorofare, NJ 08086

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

<b>EDITORIAL POLICY STATEMENT</b>	<b>Duplicate Publication of a Manuscript</b>	341
	Richard P. Wenzel, MD, MSc; Dennis G. Maki, MD; Sue Crow, MSN, RN, CIC; William Schaffner, MD; John E. McGowan, Jr., MD;	
<b>ORIGINAL ARTICLES</b>	<b>Control of Epidemic Methicillin-Resistant <i>Staphylococcus aureus</i></b>	343
	Katherine A. Murray-Leisure, MD; Sandra Geib, RN; Diane Graceley; Arline B. Rubin-Slutsky, RN; Narendra Saxena, MD; H. Arnold Muller, MD; Bruce H. Hamory, MD	
	<b>Adverse Exposures and Universal Precautions Practices Among a Group of Highly Exposed Health Professionals</b>	351
	Mary E. Willy, MPH, BSN; Gita L. Dhillon, MS, CNM; Nancy L. Loewen, MS, CNM; Robert A. Wesley, PhD; David K. Henderson, MD	
<b>SPECIAL SECTIONS</b>	<b>Special Commentaries</b>	357
	<b>The Influenza Vaccination Demonstration Project: An Expanded Policy Goal</b>	
	David S. Fedson, MD	
	<b>Infection Control for Home Health</b>	362
	Bryan Simmons, MD; Martha Trusler, RN; Jane Roccaforte, MD; Philip Smith, MD; Rebecca Scott, RN	
	<b>AIDS</b>	371
	<b>Risky Business: Using Necessarily Imprecise Casualty Counts to Estimate Occupational Risks for HIV-1 Infection</b>	
	Susan E. Beekmann, BS; Barbara J. Fahey, BSN; Julie L. Gerberding, MD; David K. Henderson, MD	
	<b>Emporiatics</b>	380
	<b>Emporiatics: Protecting Travelers From Malaria</b>	
	Mary D. Nettleman, MD	
	<b>Statistics for Hospital Epidemiology</b>	384
	<b>Practical Considerations in Designing Data Collection Forms</b>	
	Patricia A. Wasek, BA	
<b>DEPARTMENTS</b>	<b>Letters to the Editor</b>	334
	<b>Calendar of Events</b>	390
	<b>SHEA Newsletter</b>	391
	<b>Classified Marketplace</b>	Cover 3

**The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.**

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated 6900 Grove Road Thorofare New Jersey 08086 Telephone (609) 848-1000

Copyright 1990: All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

Subscriptions: Requests should be addressed to the publisher (except Japan) Japan contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the US and possessions: Individual One year—\$60.00. Two years—\$95.00. Three years—\$125.00. Institutional One year—\$70.00. Two years—\$110.00. Three years—\$150.00. Canada \$18.00 additional each year. All other countries \$30.00 additional each year. Single copies of current issues may be obtained for \$8.00, United States and possessions; \$16.00 all other countries.

Reprints: All requests to reprint or use material published herein should be addressed to Lester J. Robeson, SLACK Incorporated, 6900 Grove Road Thorofare, NJ 08086. For reprint orders and prices contact Fran Micalletti at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy plus 5¢ per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes or for creating new collective works.

**Change of address:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points. Postmaster: Send address changes to SLACK Incorporated, 6900 Grove Road Thorofare, NJ 08086.

As of Volume 1 Number 1 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents—Clinical Practice Hospital Literature index Cumulative Index to Nursing and Allied Health Literature and Nursing Abstracts.



**EDITORIAL OFFICES**

Vanderbilt University School of Medicine  
A-1131 Medical Center North  
Nashville, TN 37232-2637  
(615) 343-1095; (615) 343-1882 (FAX)  
Email: iche@mcmail.vanderbilt.edu

**EDITOR**

Michael D. Decker, MD, MPH

**MANAGING EDITOR**

Susan Cantrell

**STATISTICAL EDITOR**

Beverly G. Mellen, PhD

**SENIOR ASSOCIATE EDITORS**

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

**ASSOCIATE EDITORS**

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

**SECTION EDITORS****Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

**Disinfection and Sterilization**

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

**Emerging Infectious Diseases**

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

**From the Laboratory**

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

**Information Management**

John A. Sellick, DO

Buffalo, New York

**The International Perspective**

Mary D. Nettleman, MD, MS

Richmond, Virginia

**Issues in Surgery**

James T. Lee, MD, PhD

St. Paul, Minnesota

**Medical News**

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

**Practical Healthcare Epidemiology**

Loreen A. Herwaldt, MD

Iowa City, Iowa

**SHEA News**

Murray D. Batt, MD

Clarksburg, West Virginia

**Statistics for Hospital Epidemiology**

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

**Topics in Long-Term Care**

Philip W. Smith, MD

Omaha, Nebraska

**Topics in Occupational Medicine**

David Weber, MD, MPH

Chapel Hill, North Carolina

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

**EDITORIAL ADVISORY BOARD**

- Jacques F. Acar, MD Paris, France  
J. Wesley Alexander, MD Cincinnati, Ohio  
Paul Arnow, MD Chicago, Illinois  
Graham A.J. Ayliffe, MD Birmingham, United Kingdom  
Neil L. Barg, MD Yakima, Washington  
Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia  
John M. Boyce, MD Providence, Rhode Island  
Professor Dr. Ilja Braveny Munich, Federal Republic of Germany  
Charles Bryan, MD Columbia, South Carolina  
Christian Brun-Buisson, MD Creteil, France  
Donald E. Craven, MD Boston, Massachusetts  
Sue Crow, MSN, RN, CIC Shreveport, Louisiana  
Franz Daschner, MD Freiburg, Federal Republic of Germany  
Leigh G. Donowitz, MD Charlottesville, Virginia  
Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin  
Theodore C. Eickhoff, MD Denver, Colorado  
Bruce Farber, MD Manhasset, New York  
Victoria J. Fraser, MD St. Louis, Missouri  
Peter C. Fuchs, MD, PhD Black Butte, Oregon  
Richard A. Garibaldi, MD Farmington, Connecticut  
Velvl Greene, PhD, MPH Beer Sheva, Israel  
Robert Gaynes, MD Atlanta, Georgia  
David W. Gregory, MD Nashville, Tennessee  
David K. Henderson, MD Bethesda, Maryland  
Peter N.R. Heseltine, MD Los Angeles, California  
Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina  
Marguerite McMillan Jackson, RN, PhD San Diego, California  
Janine Jagger, MPH, PhD Charlottesville, Virginia  
William R. Jarvis, MD Atlanta, Georgia  
Douglas S. Kernodle, MD Nashville, Tennessee  
Robert H. Latham, MD Nashville, Tennessee  
Lewis B. Lefkowitz, MD Nashville, Tennessee  
Hsieh-Shong Leu, MD, MSc Taipei, Taiwan  
Jack Levy, MD Brussels, Belgium  
Victor Lorian, MD Bronx, New York  
Dennis G. Maki, MD Madison, Wisconsin  
Professor Dr. Walter Marget Munich, Federal Republic of Germany  
William J. Martone, MD Bethesda, Maryland  
Allison McGeer, MD Toronto, Ontario, Canada  
John E. McGowan, Jr., MD Atlanta, Georgia  
Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada  
Raf Mertens, MD Brussels, Belgium  
Robert R. Muder, MD Pittsburgh, Pennsylvania  
Joseph M. Mylotte, MD, CIC Buffalo, New York  
Lindsay Nicolle, MD Winnipeg, Manitoba, Canada  
Juhani Ojajarvi, MD Helsinki, Finland  
Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota  
Jan Evans Patterson, MD San Antonio, Texas  
Sindy M. Paul, MD Trenton, New Jersey  
Michael A. Pfaller, MD Iowa City, Iowa  
Samuel Ponce de Leon, MD, MSc Mexico City, Mexico  
Isaam Raad, MD Houston, Texas  
Manfred L. Rotter, MD, DipBact Vienna, Austria  
Theodore Sacks, MD Jerusalem, Israel  
William E. Scheckler, MD Madison, Wisconsin  
Kent Sepkowitz, MD New York City, New York  
Denis Spelman, MD Prahran Victoria, Australia  
Michael L. Tapper, MD New York, New York  
Clyde Thornsberry, PhD Brentwood, Tennessee  
Professor Leonid P. Titov Minsk, Republic of Belarus  
Timothy R. Townsend, MD Millwood, Virginia  
Antoni Trilla, MD, PhD Barcelona, Spain  
Professor Wang Shu-Qun Beijing, People's Republic of China  
J. John Weems, Jr., MD Greenville, South Carolina  
Robert A. Weinstein, MD Chicago, Illinois  
Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany  
Sergio B. Wey, MD São Paulo, Brazil  
Rebecca Wurtz, MD Evanston, Illinois

**SLACK Incorporated**

6900 Grove Road  
Thorofare, New Jersey 08086  
(609) 848-1000

**Vice President/Group Publisher**

Richard N. Roash

**Publisher**

John C. Carter

**Editorial Director**

Jennifer Kilpatrick

**Production Editor**

Shirley P. Strunk, ELS

**Assistant Editor**

Eileen C. Anderer

**Circulation Manager**

Lester J. Robeson, CCCC

**Production Director**

Christine Malin

**Production Coordinator**

Joanne Patterson

**Publishing Director/ Advertising**

Wayne McCourt

**Pharmaceutical Group Sales Director**

Michael LoPresti

**Advertising Sales Representative**

Jennine Kane

**Classified/Recruitment Sales Manager**

Michele Burch

# "Synergism.."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.\* Patented Sporicidin disinfects with substantially less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temperature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77° F.

Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

\* *Journal of Clinical Microbiology*,  
November 1985, p. 735 - 739



**Sporicidin**  
INTERNATIONAL

12000 Old Georgetown Road, Rockville, Maryland 20847